HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Endoxifen shows promise in breast cancer.

Abstract
In a phase I trial of endoxifen, a metabolite of tamoxifen, multiple patients with estrogen receptor-positive breast cancer that was resistant to treatment with aromatase inhibitors had partial responses or long-lasting stable disease.
Authors
JournalCancer discovery (Cancer Discov) Vol. 4 Issue 2 Pg. OF1 (Feb 2014) ISSN: 2159-8290 [Electronic] United States
PMID24501306 (Publication Type: News)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • 4-hydroxy-N-desmethyltamoxifen
Topics
  • Antineoplastic Agents, Hormonal (administration & dosage, adverse effects, therapeutic use)
  • Breast Neoplasms (drug therapy, pathology)
  • Female
  • Humans
  • Selective Estrogen Receptor Modulators (administration & dosage, adverse effects, therapeutic use)
  • Tamoxifen (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: